SCHEMBL14617543

SCHEMBL14617543

CS(=O)(=O)c1ncc(C(F)(F)F)c(CCc2ccccc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ULK1 O75385 1/20 0.43
▸ PTK2 Q05397 4/20 0.41
▸ SDHB P21912 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ S1PR4 O95977 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ S1PR1 P21453 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ STAT3 P40763 1/20 0.39
▸ STAT1 P42224 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TLR9 Q9NR96 1/20 0.39
▸ PTGS2 P35354 5/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15569325 0.82 PTK2 (0.44) PTK2
SCHEMBL17027345 0.79 PTK2 (0.54) PTK2
SCHEMBL14576462 0.79 SLC7A5 (0.43) PTK2SDHBSTAT3
SCHEMBL12478743 0.77 PTK2 (0.44) PTK2
SCHEMBL14643154 0.75 SDHB (0.49) PTK2SDHBMEN1S1PR4LMNA
SCHEMBL25239800 0.72 SDHB (0.46) SDHBMEN1S1PR4LMNATP53
SCHEMBL669825 0.72 ULK1 (0.61) ULK1PTK2MEN1KMT2AHSD17B10
SCHEMBL30397985 0.72 SDHB (0.46) SDHBMEN1S1PR4LMNATP53
SCHEMBL24087394 0.72 SDHB (0.39) SDHBMEN1S1PR4LMNATP53
SCHEMBL14617540 0.71 SDHB (0.39) PTK2SDHBMEN1S1PR4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9421205-B2 FAK inhibitors Cancer Therapeutics CRC Pty Ltd. (AU) 2016-08-23 — — US disclosed
US-9174946-B2 Selective FAK inhibitors CANCER THERAPEUTICS CRC PTY LTD (AU) 2015-11-03 — — US disclosed
US-9120761-B2 Selective FAK inhibitors CANCER THERAPEUTICS CRC PTY LTD (AU) 2015-09-01 — — US disclosed
US-20150231135-A1 FAK INHIBITORS Cancer Therapeutics CRC Pty Ltd. (AU) 2015-08-20 — — US disclosed
US-9012461-B2 FAK inhibitors CANCER THERAPEUTICS CRC PTY LTD (AU) 2015-04-21 — — US disclosed
US-20130022594-A1 SELECTIVE FAK INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2013-01-24 — — US disclosed
US-20130022594-A1 SELECTIVE FAK INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2013-01-24 — — US disclosed
US-20130017194-A1 FAK INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2013-01-17 — — US disclosed
US-20130017194-A1 FAK INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2013-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130017194-A1 FAK INHIBITORS PTK2, CTTN, SRC ULK1 2464/4885PTK2 1/4885SDHB 3248/4885
US-20130022594-A1 SELECTIVE FAK INHIBITORS PTK2, CTTN, SRC ULK1 2521/4885PTK2 1/4885SDHB 3412/4885
US-20150231135-A1 FAK INHIBITORS PTK2, CTTN, SRC ULK1 2321/4885PTK2 1/4885SDHB 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback